EA200400501A1 - Способ снижения заболеваемости и смертности, связанных с критическими состояниями - Google Patents

Способ снижения заболеваемости и смертности, связанных с критическими состояниями

Info

Publication number
EA200400501A1
EA200400501A1 EA200400501A EA200400501A EA200400501A1 EA 200400501 A1 EA200400501 A1 EA 200400501A1 EA 200400501 A EA200400501 A EA 200400501A EA 200400501 A EA200400501 A EA 200400501A EA 200400501 A1 EA200400501 A1 EA 200400501A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reduce
critical conditions
disease
mortality associated
mortality
Prior art date
Application number
EA200400501A
Other languages
English (en)
Russian (ru)
Inventor
Суад Эфендик
Джозеф Энтони Якубовский
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200400501A1 publication Critical patent/EA200400501A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EA200400501A 2001-10-01 2002-09-19 Способ снижения заболеваемости и смертности, связанных с критическими состояниями EA200400501A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32633001P 2001-10-01 2001-10-01
PCT/US2002/028123 WO2003028626A2 (en) 2001-10-01 2002-09-19 Glucagon-like peptides (glp-1) and treatment of respiratory distress

Publications (1)

Publication Number Publication Date
EA200400501A1 true EA200400501A1 (ru) 2005-06-30

Family

ID=23271764

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400501A EA200400501A1 (ru) 2001-10-01 2002-09-19 Способ снижения заболеваемости и смертности, связанных с критическими состояниями

Country Status (19)

Country Link
US (2) US20040235726A1 (cs)
EP (1) EP1443952A4 (cs)
JP (1) JP2005523877A (cs)
KR (1) KR20040040482A (cs)
CN (1) CN1561224A (cs)
BR (1) BR0212620A (cs)
CA (1) CA2462543A1 (cs)
CZ (1) CZ2004441A3 (cs)
EA (1) EA200400501A1 (cs)
EC (1) ECSP045044A (cs)
HR (1) HRP20040258A2 (cs)
HU (1) HUP0600437A2 (cs)
IL (1) IL160631A0 (cs)
MX (1) MXPA04002996A (cs)
NO (1) NO20041351L (cs)
PL (1) PL373846A1 (cs)
SK (1) SK1432004A3 (cs)
WO (1) WO2003028626A2 (cs)
ZA (1) ZA200402557B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
AU2003203146A1 (en) * 2002-02-07 2003-09-02 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
CA2551039C (en) 2003-12-16 2013-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues of glp-1
TWI364292B (en) 2005-06-30 2012-05-21 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
DE102009024229B3 (de) * 2009-06-08 2010-10-14 Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat. Indikationseinrichtung zur automatisierten Bestimmung des individuellen Inkretin-Sensitivitäts-Indexes eines Probanden
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
ES2810153T3 (es) * 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
US20230218556A1 (en) * 2020-05-01 2023-07-13 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
CN116847868A (zh) * 2021-01-29 2023-10-03 韩美药品株式会社 用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors

Also Published As

Publication number Publication date
WO2003028626A2 (en) 2003-04-10
CA2462543A1 (en) 2003-04-10
PL373846A1 (en) 2005-09-19
BR0212620A (pt) 2005-09-20
CN1561224A (zh) 2005-01-05
NO20041351D0 (no) 2004-03-31
EP1443952A4 (en) 2005-09-07
ECSP045044A (es) 2004-04-28
WO2003028626A3 (en) 2003-10-09
MXPA04002996A (es) 2004-07-15
US20080032932A1 (en) 2008-02-07
CZ2004441A3 (cs) 2004-11-10
KR20040040482A (ko) 2004-05-12
HUP0600437A2 (en) 2006-09-28
SK1432004A3 (sk) 2005-03-04
US20040235726A1 (en) 2004-11-25
EP1443952A2 (en) 2004-08-11
ZA200402557B (en) 2005-05-09
HRP20040258A2 (en) 2004-12-31
NO20041351L (no) 2004-06-30
IL160631A0 (en) 2004-07-25
JP2005523877A (ja) 2005-08-11

Similar Documents

Publication Publication Date Title
EA200400501A1 (ru) Способ снижения заболеваемости и смертности, связанных с критическими состояниями
EA200300644A1 (ru) Слитые белки glp-1
HRP20020996B1 (en) Glucagon-like peptide-1 analogs
TW200626613A (en) Analogues of GLP-1
DK1137666T3 (da) GLP-1-analoger
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
ATE536881T1 (de) Glp-1, exendin-4, peptid-analoga und verwendungen davon
EA200001037A1 (ru) Легочная и назальная доставка ралоксифена
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
EA200300459A1 (ru) Новые, применяемые в качестве медикаментов антихолинергические средства, а также способ их получения
AU7485301A (en) Methods for refolding proteins containing free cysteine residues
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
EA200301223A1 (ru) Лекарственные формы окскарбазепина
DK1349578T3 (da) Kombinationspræparat indeholdende en biguanin (metformin) og arginin
ATE403726T1 (de) Cytokin-proteinfamilie
ATE481420T1 (de) Il-21-derivate
DE60332425D1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
EA200201232A1 (ru) Производные сульфонамида
EA200201234A1 (ru) Производные сульфонамида
SE0201938D0 (sv) New process
ATE374811T1 (de) Hühner-astrovirus typ 2
ES2163142T3 (es) Nuevos peptidos y agente neotropico.
TH51594A (th) สารประกอบเปปไทด์-1 แอนาลอกคล้ายกับกลูคากอน
DE69942305D1 (de) Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos